Bellecapital International Ltd. Denali Therapeutics Inc. Transaction History

Bellecapital International Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 21, 2021	SELL	$48.48 - $78.23 $370,581 - $597,990	-7,644 Closed	0 $0
Q4 2020 Jan 14, 2021	SELL	$36.89 - $93.56 $153,646 - $389,677	-4,165 Reduced 35.27%	7,644 $640,000
Q3 2020 Oct 16, 2020	BUY	$23.13 - $38.84 $273,142 - $458,661	11,809 New	11,809 $423,000

236

120M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.8B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Bellecapital International Ltd., based on Form 13F filings with the SEC.

Stay updated on Bellecapital International Ltd. with notifications on news.